You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?
|
|---|---|
| Published in |
Genetic Vaccines and Therapy, October 2012
|
| DOI | 10.1186/1479-0556-10-9 |
| Pubmed ID | |
| Authors |
Sarfraz Ahmad, Paul Sweeney, Gerald C Sullivan, Mark Tangney |
| Abstract |
Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and cellular immunity. This immune activation has been proven effective in animal models and initial clinical trials are encouraging. However, to validate the role of DNA vaccination in currently available PCa management paradigms, strong clinical evidence is still lacking. This article provides an overview of the basic principles of DNA vaccines and aims to provide a summary of preclinical and clinical trials outlining the benefits of this immunotherapy in the management of PCa. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Unknown | 29 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 30% |
| Researcher | 5 | 17% |
| Lecturer | 3 | 10% |
| Student > Ph. D. Student | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Other | 6 | 20% |
| Unknown | 2 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 23% |
| Biochemistry, Genetics and Molecular Biology | 6 | 20% |
| Medicine and Dentistry | 6 | 20% |
| Immunology and Microbiology | 5 | 17% |
| Arts and Humanities | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 2 | 7% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2012.
All research outputs
#12,861,953
of 22,681,577 outputs
Outputs from Genetic Vaccines and Therapy
#35
of 43 outputs
Outputs of similar age
#89,496
of 172,685 outputs
Outputs of similar age from Genetic Vaccines and Therapy
#2
of 4 outputs
Altmetric has tracked 22,681,577 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 43 research outputs from this source. They receive a mean Attention Score of 4.5. This one scored the same or higher as 8 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,685 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.